昭衍新藥(06127.HK):建議採納股份激勵計劃(H股)
格隆匯4月29日丨昭衍新藥(06127.HK)發佈公吿,2022年4月28日,董事會議決批准股份激勵計劃及建議採納股份激勵計劃以供股東批准。股份激勵計劃將與公司已經或可能採納的其他股份激勵計劃並行。概無新股份根據股份激勵計劃發行或配發。
公司現時並無有關H股的任何類型股權激勵計劃。董事會認為,股份激勵計劃可連同有關A股的其他股權激勵計劃,有助於為僱員及股東設立及改善利益共享機制,提升企業管治水平,提高公司僱員的凝聚力及競爭力,調動僱員的積極性及創造力,促進公司的長期、持續及健康發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.